Back to Oncology
Oncologyv1949_originalEvidence-Based

Karnofsky Performance Status Scale

Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.

Clinical Input Parameters

percentage
Clinical Assessment
Awaiting Parameters
functional status
—category
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Karnofsky Performance Status Scale is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Direct assessment using standardized 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%) based on functional capabilities

Clinical Pearls & Practice Notes

  • Originally developed in 1949 by David Karnofsky and colleagues for nitrogen mustard chemotherapy studies
  • Widely used in oncology for treatment eligibility, clinical trial enrollment, and prognosis assessment
  • Correlates with chemotherapy tolerance, survival outcomes, and quality of life measures
  • Higher scores (80-100%) generally indicate good performance status suitable for aggressive treatments
  • Lower scores (0-40%) may indicate need for palliative care or less intensive treatments
  • ECOG Performance Status (0-4 scale) is a simpler alternative but Karnofsky provides more granular assessment
  • Subject to interobserver variability; standardized assessment guidelines improve reliability
  • May lack sensitivity in elderly cancer patients where 80% score ECOG 0-1 despite comorbidities

Evidence & Literature Citations

  1. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634-656.
  2. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 196.
  3. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-193.
  4. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45(8):2220-2224.

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.